Moleculo

First Investment: 2015

EXIT - Acquisition (Illumina: ILMN)

Moleculo’s founders developed new library prep and analysis techniques that allowed them to assemble short sequences of DNA base-pair information into accurate, synthetic long reads. Illumina acquired the company in 2013.

Explore Companies

Sidewinder Therapeutics

Advancing precision bispecific antibody-drug conjugates to treat cancer

Newleos Therapeutics

Transforming the treatment of anxiety and other neuropsychiatric disorders

Grove Biopharma

Putting protein-like drugs inside cells to fight cancer and neurodegeneration

Syntax Bio

Programming stem cells to differentiate into desired cell types, faster